-
-
-
-
-
-
-
Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald After Q2 Results
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
-
-
-
-
-
-
-
Summit Therapeutics (SMMT) Reiterated at Buy by Stifel on HARMONi-6 'Win'
-
-
-
-
-
-
-
Summit Therapeutics plc (SMMT) PT Lowered to $23 at H.C. Wainwright
-
-
-
-
-
-
-
Summit Therapeutics to present ivonescimab data at ELCC 2026
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
-
-
-
-
-
-
Summit Therapeutics' (SMMT) HARMONi-2 Important 2026 Catalyst - Cantor Fitzgerald
-
448,168 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

